Lin Lin1, Xinyue Tang2, Jinjin Wei2, Fei Dai2, Guangbin Sun2. 1. Department of Otorhinolaryngology-Head and Neck Surgery, Huashan Hospital of Fudan University, Shanghai, China. Electronic address: linlinhsn@aliyun.com. 2. Department of Otorhinolaryngology-Head and Neck Surgery, Huashan Hospital of Fudan University, Shanghai, China.
Abstract
OBJECTIVE: To evaluate the efficacy of xylitol nasal irrigation (XNI) treatment on chronic rhinosinusitis (CRS) and to investigate the effect of XNI on nasal nitric oxide (NO) and inducible nitric oxide synthase (iNOS) mRNA in maxillary sinus. MATERIALS AND METHODS: Patients with CRS were enrolled and symptoms were assessed by Visual Analog Scale (VAS) and Sino-Nasal Outcome Test 22 (SNOT-22). Nasal NO and iNOS mRNA in the right maxillary sinus were also examined. Then, they were treated with XNI (XNI group) or saline nasal irrigation (SNI, SNI group) for 30days, after which their symptoms were reassessed using VAS and SNOT-22, and nasal NO and iNOS mRNA in the right maxillary sinus were also reexamined. RESULTS: Twenty-five out of 30 patients completed this study. The scores of VAS and SNOT-22 were all reduced significantly after XNI treatment, but not after SNI. The concentrations of nasal NO and iNOS mRNA in the right maxillary sinus were increased significantly in XNI group. However, significant changes were not found after SNI treatment. Furthermore, there were statistical differences in the assessments of VAS and SNOT-22 and the contents of nasal NO and iNOS mRNA in the right maxillary sinus between two groups. CONCLUSIONS: XNI results in greater improvement of symptoms of CRS and greater enhancement of nasal NO and iNOS mRNA in maxillary sinus as compared to SNI.
OBJECTIVE: To evaluate the efficacy of xylitol nasal irrigation (XNI) treatment on chronic rhinosinusitis (CRS) and to investigate the effect of XNI on nasal nitric oxide (NO) and inducible nitric oxide synthase (iNOS) mRNA in maxillary sinus. MATERIALS AND METHODS:Patients with CRS were enrolled and symptoms were assessed by Visual Analog Scale (VAS) and Sino-Nasal Outcome Test 22 (SNOT-22). Nasal NO and iNOS mRNA in the right maxillary sinus were also examined. Then, they were treated with XNI (XNI group) or saline nasal irrigation (SNI, SNI group) for 30days, after which their symptoms were reassessed using VAS and SNOT-22, and nasal NO and iNOS mRNA in the right maxillary sinus were also reexamined. RESULTS: Twenty-five out of 30 patients completed this study. The scores of VAS and SNOT-22 were all reduced significantly after XNI treatment, but not after SNI. The concentrations of nasal NO and iNOS mRNA in the right maxillary sinus were increased significantly in XNI group. However, significant changes were not found after SNI treatment. Furthermore, there were statistical differences in the assessments of VAS and SNOT-22 and the contents of nasal NO and iNOS mRNA in the right maxillary sinus between two groups. CONCLUSIONS:XNI results in greater improvement of symptoms of CRS and greater enhancement of nasal NO and iNOS mRNA in maxillary sinus as compared to SNI.
Authors: Samuel J M Hale; Brett Wagner Mackenzie; Christian A Lux; Kristi Biswas; Raymond Kim; Richard G Douglas Journal: Front Pharmacol Date: 2022-06-13 Impact factor: 5.988
Authors: Victor B Hsue; Kyohei Itamura; Arthur W Wu; Elisa A Illing; Kevin J Sokoloski; Bree A Weaver; Benjamin P Anthony; Nathan Hughes; Jonathan Y Ting; Thomas S Higgins Journal: Adv Exp Med Biol Date: 2021 Impact factor: 2.622
Authors: Shruti Bansal; Colleen B Jonsson; Shannon L Taylor; Juan Manuel Figueroa; Andrea Vanesa Dugour; Carlos Palacios; Julio César Vega Journal: PLoS One Date: 2021-11-19 Impact factor: 3.240
Authors: Do-Yang Park; Ji Ho Choi; Dong-Kyu Kim; Yong Gi Jung; Sue Jean Mun; Hyun Jin Min; Soo Kyoung Park; Jae-Min Shin; Hyung Chae Yang; Seung-No Hong; Ji-Hun Mo Journal: Clin Exp Otorhinolaryngol Date: 2022-02-15 Impact factor: 3.372
Authors: Evangelina Soler; Amanda de Mendoza; Víctor I Cuello; Maria G Silva-Vetri; Zoilangel H Núñez; Ramsés G Ortega; Syed A Rizvi; Marcos Sanchez-Gonzalez; Gustavo Ferrer Journal: Cureus Date: 2022-07-23